Yao syndrome (YAOS) (formerly called NOD2-associated autoinflammatory disease) is an autoinflammatory syndrome involving episodes of fever and abnormal inflammation affecting many parts of the body, particularly the skin, joints, and gastrointestinal system. Signs and symptoms
Arthralgia (Arthritis)
Fever
Diarrhea
Abdominal Pain
Keratoconjunctivitis Sicca (Dry eyes)
Pleurisy
Idiopathic Pericarditis
Xerostomia (Dry mouth)
Erythematous Plaques
Dermatitis

Diagnostic criteria
Yao syndrome is diagnosed if 2 major criteria, at least one minor criterion, the molecular criterion, and exclusion criteria are fulfilled. Treatment
A study to determine the effectiveness of Novartis pharmaceutical drug Canakinumab was conducted. In this study, canakinumab was effective in patients with YAOS, and thus clinical trial of canakinumab may be warranted as a therapeutic option for this disease. Inheritance
Yao Syndrome inheritance is classified as Multifactorial Inheritance. References
External links

MedGen-Yao Syndrome
Genetics Home Reference-Yao Syndrome
Taking the two substances simultaneously is inadvisable.Verteporfin does not appear to be metabolized by Cytochrome P450 enzymes, therefore not affecting Cytochrome P450 metabolism of other drugs. Shortages
In May 2020, a low manufacturing capacity caused disruption. This effected the usage of verteporfin among providers and patients in Europe. The EMA expected normal manufacturing to return by the first quarter 2022. Potential against scarring
Verteporfin is FDA approved. Verteporfin is a YAP pathway inhibitor. Verteporfin displays a wide spectrum of anti-fibrotic properties. Verteporfin prevents fibrosis in several human organs. Verteporfin was first noted as a drug that blocked cell proliferation in the liver. It is an inhibitor of fibrosis in patients with persistent cholestasis. Research has highlighted that verteporfin decreased expression of fibrotic genes in fibroblasts collected from nodules of patients suffering from Dupuytrens contracture. In 2018 information revealed verteporfin stopped fibrosis in the lung. Verteporfin is a marketed drug with a good safety profile. Physicians use verteporfin off-label. In 2018, physicians described the off-label usage for Peyronies disease as an interesting step.In 2021, scientists tested verteporfin to reveal if the drug would prevent scar tissue in skin. The testing of verteporfin on humans cleft lips was due to occur in late 2021. References
External links
"Visudyne". Novartis.